Skip to main content
ABL Bio Inc. logo

ABL Bio Inc. — Investor Relations & Filings

Ticker · 298380 ISIN · KR7298380007 LEI · 9884007BRC71Y64NK235 KO Professional, scientific and technical activities
Open in API
Filings indexed 368 across all filing types
Latest filing 2025-10-15 Capital/Financing Update
Country KR South Korea
Listing KO 298380

About ABL Bio Inc.

https://www.ablbio.com

ABL Bio Inc. is a clinical-stage biotechnology company specializing in the development of bispecific antibody therapeutics for immuno-oncology and neurodegenerative diseases. The company leverages several proprietary platforms. For central nervous system disorders, its 'Grabody-B' technology is a blood-brain barrier (BBB) penetrating shuttle designed to enhance drug delivery to the brain. In immuno-oncology, ABL Bio develops 4-1BB based bispecific antibodies aimed at minimizing toxicity and overcoming resistance to existing immunotherapies. The company is also advancing a pipeline of antibody-drug conjugates (ADCs) with an improved therapeutic index for conditions such as rare blood cancers. ABL Bio actively progresses its therapeutic candidates through clinical development.

Recent filings

Filing Released Lang Actions
[기재정정]유상증자결정(종속회사의주요경영사항)
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding a capital increase (유상증자결정) by a subsidiary company, NEOK Bio, Inc., which is 100% owned by the parent company, 에이비엘바이오. It includes specifics such as the number and type of shares issued, the purpose of the capital increase (operating funds for clinical and R&D activities), the pricing, the board resolution date, and other related financial details. The document is not a full financial report but a specific update on a financing activity related to share issuance by a subsidiary. The document length is 4200 characters, which is relatively short but contains substantive details about the capital increase decision. This fits the definition of a Capital/Financing Update (CAP) rather than a general regulatory filing or announcement of a report. Therefore, the appropriate classification is CAP with high confidence.
2025-10-15 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is titled '주식등의 대량보유상황보고서(일반)' which translates to 'Report on Large Shareholding Status (General)'. It contains detailed information about the number of shares held, shareholding ratios, changes in shareholding, and related contractual details. It references specific dates and includes data about the major shareholder and related parties. The document is a regulatory filing related to disclosure of large shareholdings as required by capital market laws. It is not an annual report, earnings release, or any other financial report type. It is a notification of major shareholding changes, which fits the category 'Major Shareholding Notification' (Code: MRQ). The document length and detail confirm it is the report itself, not just an announcement or certification.
2025-10-02 Korean
타법인주식및출자증권취득결정
Capital/Financing Update Classification · 78% confidence The document is an official corporate disclosure titled “타법인주식및출자증권취득결정” (Decision to Acquire Shares and Equity Securities of Another Company). It details a paid-in capital participation (유상증자 참여) in NEOK Bio, Inc. including number of shares, acquisition amount, timing, board resolution, and investment purpose. This is not a full financial report nor merely an announcement of publication; it’s a real capital/financing transaction notification. It does not involve repurchasing its own shares (POS) or a regulatory certification (RNS), nor is it a governance or management change. It most closely matches “Capital/Financing Update” which covers updates on financing activities or capital structure changes. Hence the classification is CAP.
2025-09-26 Korean
유상증자결정(종속회사의주요경영사항)
Share Issue/Capital Change Classification · 91% confidence The document is a statutory corporate announcement detailing the terms of a paid-in capital increase (유상증자결정) by a subsidiary, including share type, number of new shares, issue price, purpose of funds, board resolution date, etc. This fits the definition of a share issue/capital change announcement rather than an earnings release, AGM materials, or full financial report. Therefore it is classified as Share Issue/Capital Change (SHA).
2025-09-26 Korean
주식매수선택권행사
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from ABL Bio regarding the exercise of stock options (주식매수선택권행사). It details the number of shares exercised, the exercise price, the individuals involved (directors and employees), and the impact on the total number of issued shares. This type of disclosure regarding capital changes through stock option exercises is classified as a share issue or capital change announcement.
2025-09-09 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service (FSS). This type of filing is a mandatory disclosure for company insiders (directors/executives) reporting changes in their shareholdings, which corresponds to the 'Director's Dealing' category.
2025-09-09 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.